Results 81 to 90 of about 14,856,428 (286)

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Leukemia Research Reports
Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV ...
Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki   +3 more
doaj   +1 more source

ZBTB18 Dysfunction Promotes Neuropathic Pain via CHD4‐based Epigenetic Disinhibition of CLIC1 Channels in Sensory Neurons

Advanced Science, EarlyView.
In this study, we identify a novel functional role of ZBTB18 in regulating trigeminal‐mediated neuropathic pain. Nerve injury reduces ZBTB18 in trigeminal ganglion neurons, impairing CHD4/NuRD recruitment and de‐repressing Clic1. Elevated CLIC1 enhances chloride channel activity and neuronal hyperexcitability, thereby driving pain.
Shoupeng Wang, Zitong Huang, Yu Tao, Yunmei Zhang, Yufang Sun, Dongsheng Jiang, Weiwei Lu, Fuhai Ji, Gang Chen, Min Xu, Yuan Zhang, Jin Tao   +11 more
wiley   +1 more source

B-cell lymphoma showing typical features of angioimmunoblastic T-cell lymphoma [PDF]

, 2008
We present a 52-year-old man who was diagnosed with B cell-derived angioimmunoblastic lymphoma. He was admitted with systemic, including mediastinal and para-aortic, lymphadenopathy, fever and skin itching.
Ozawa, Keiya, Mori, Masaki, Muroi, Kazuo, Nagai , Tadashi, Furukawa , Yusuke, Takatoku, Masaaki   +5 more
core  

Mechanisms of Rejection of High Grade B cell Lymphoma in Mice [PDF]

, 2008
The incidence of high grade B cell lymphoma in western countries has increased over the last decades. Improvement of conventional chemotherapy regimens has significantly contributed to prolonged 5-year survival rates which currently reach around 60 ...
Sukumar, Madhusudhanan
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

, 2008
Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Several multicenter phase 3 trials; will incorporate this scheme.
Coenen, Jules L., Rosati, Stefano, van Imhoff, Gustaaf W., Kluin-Nelemans, Hanneke C., Boers, James E.   +4 more
core   +1 more source

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

Haematologica, 2018
Due to heterogeneous morphological and immunophenotypic features, approximately 50% of peripheral T-cell lymphomas are unclassifiable and categorized as peripheral T-cell lymphomas, not otherwise specified.
Meng-Meng Ji, Yao-Hui Huang, Jin-Yan Huang, Zhao-Fu Wang, Di Fu, Han Liu, Feng Liu, Christophe Leboeuf, Li Wang, Jing Ye, Yi-Ming Lu, Anne Janin, Shu Cheng, Wei-Li Zhao   +13 more
doaj   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

Advanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu, Xingwei Xie, Xiaohuan Wu, Suidong Ouyang, Yang Zhou, Kang Wen, Yutong Zhong, Yuyang Chen, Handuo Wang, Yuan Gao, Ling Jiang, Hui Li, Wenli Zhao, Abai Xu, Enguang Bi   +14 more
wiley   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source